Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 6/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24571999 | 1.00 | KMT2A (0.40) | KMT2ASYKMAPK8AXLBTK | |
| SCHEMBL24571997 | 0.86 | KMT2A (0.38) | KMT2ASYKMAPK8AXLMAPK9 | |
| SCHEMBL29673376 | 0.86 | KMT2A (0.38) | KMT2ASYKMAPK8AXLMAPK9 | |
| SCHEMBL10050287 | 0.85 | KMT2A (0.50) | KMT2ASYKMAPK8AXLTYRO3 | |
| SCHEMBL31612124 | 0.85 | KMT2A (0.50) | KMT2ASYKMAPK8AXLTYRO3 | |
| SCHEMBL23611089 | 0.84 | MAPK8 (0.42) | KMT2ASYKMAPK8AXLMAPK9 | |
| SCHEMBL23620506 | 0.84 | MAPK8 (0.42) | KMT2ASYKMAPK8AXLMAPK9 | |
| SCHEMBL23925200 | 0.83 | KMT2A (0.38) | KMT2ASYKMAPK8AXLBTK | |
| SCHEMBL23620531 | 0.83 | SYK (0.48) | KMT2ASYKADORA3 | |
| SCHEMBL29501988 | 0.83 | SYK (0.48) | KMT2ASYKADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114315834-B | Imidazolone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-113121538-B | Furan derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-114315834-A | Imidazolidinone derivatives and their use in medicaments | 成都百裕制药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
| WO-2021136461-A1 | PURINE DERIVATIVE AND MEDICAL USE THEREOF | 成都百裕制药股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| WO-2021136462-A1 | FURAN DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | KMT2A 3463/4885SYK 601/4885MAPK8 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.